Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(7 sites)

Canada

Cross Cancer Institute, Edmonton, Alberta

NL Health Services, St. John's, Newfoundland and Labrador

QEII Health Science Centre, Halifax, Nova Scotia

London Health Sciences Centre, London, Ontario

Princess Margaret Hospital, Toronto, Ontario

Hôpital Maisonneuve-Rosemont, Montreal, Quebec

McGill University Health Centre, Montreal, Quebec